Fig. 7
DCZ5417 inhibited tumor growth in vivo. Antitumorigenic effects of DCZ5417 in a xenograft model of MM. a H929 cells were injected subcutaneously into mice (n = 6/group) and then mice were treated with or without 15 mg/kg DCZ5417 every day for 16 days. Tumor specimens photographed with a high-definition digital camera. b and c Tumor sizes were measured every 2 days. Average and SD of the tumor volumes (cm3) versus time. d Averages and SDs of nude mouse weights versus the time (mean weight SD; 6/group). e Ki-67, Caspase-3, TUNEL and p-ERK staining of the control and DCZ5417-treated xenograft tumor tissues (original magnification: ×400). Graphs of the percentage of survival over time (until the tumor volume reached 2000 mm3) for the duration of the experiment. “Control” and “DCZ5417” represent mice bearing tumors that were treated with the vehicle or DCZ5417, respectively. f H&E staining of the control and DCZ5417-treated liver and kidney tissues in the nude mice (original magnification: ×200). g Kaplan–Meier plots of mice treated with the vehicle or DCZ5417 (n = 9/group). Data are presented as the means ± SD of 3 independent experiments. *P < 0.05, **P < 0.01 and ***P < 0.001 versus the control group